We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+4.23%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.4B
AUM Growth
+$2.4B
Cap. Flow
+$169M
Cap. Flow %
7.05%
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85

Top Buys

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$94.4M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$24M
3
AGN
Allergan plc
AGN
+$13.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$11.9M
5
MBLY
Mobileye N.V.
MBLY
+$8.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$42.1M
2
GILD icon
Gilead Sciences
GILD
+$11.5M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$11.1M
4
A icon
Agilent Technologies
A
+$6.68M
5
ADVM
Adverum Biotechnologies
ADVM
+$3.71M

Sector Composition

Rank Sector Weight
1 Healthcare 9.36%
2 Technology 0.55%
3 Energy 0.39%
4 Industrials 0.16%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
76
CALL
Heron Therapeutics
HRTX
$92M
$4.89M 0.2%
+3,360
New +$37.9K
GWPH
77
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$4.81M 0.2%
+52,776
New +$4.29M
RXII
78
DELISTED
GALENA BIOPHARMA INC COM
RXII
$4.78M 0.2%
3,436,456
+3,295,512
+2,338% +$4.58M
PCYC
79
CALL
DELISTED
PHARMACYCLICS INC
PCYC
$4.76M 0.2%
+186
New +$35.9K
MBOT icon
80
Microbot Medical
MBOT
$113M
$4.75M 0.2%
2,877
-700
-20% -$1.25M
TPST icon
81
Tempest Therapeutics
TPST
$13.9M
$4.69M 0.2%
+709
New +$94.4M
IOVA icon
82
Iovance Biotherapeutics
IOVA
$2.1B
$4.54M 0.19%
+375,234
New +$4.23M
EIGR
83
CALL
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$4.52M 0.19%
+5
New +$43.7K
OMER icon
84
CALL
Omeros
OMER
$816M
$4.47M 0.19%
+2,028
New +$46.3K
CYH icon
85
CALL
Community Health Systems
CYH
$393M
$4.44M 0.18%
1,027
+976
+1,914% +$40.4K
RGLS
86
DELISTED
Regulus Therapeutics
RGLS
$4.42M 0.18%
2,174
-762
-26% -$1.66M
INCY icon
87
PUT
Incyte
INCY
$26B
$4.38M 0.18%
478
+205
+75% +$16.9K
CLDX icon
88
PUT
Celldex Therapeutics
CLDX
$2.79B
$4.31M 0.18%
+103
New +$36.8K
MNK
89
PUT
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$4.08M 0.17%
+322
New +$36.8K
SGMO
90
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.07M 0.17%
259,741
-33,759
-12% -$522K
THC icon
91
Tenet Healthcare
THC
$22.6B
$3.98M 0.17%
+80,481
New +$3.76M
CERN
92
CALL
DELISTED
Cerner Corp
CERN
$3.93M 0.16%
+536
New +$37.1K
DYAX
93
CALL
DELISTED
DYAX CORPORATION
DYAX
$3.92M 0.16%
2,338
-1,056
-31% -$16.4K
NVAX icon
94
CALL
Novavax
NVAX
$1.21B
$3.88M 0.16%
235
+61
+35% +$9.9K
QRHC icon
95
Quest Resource Holding
QRHC
$28.3M
$3.8M 0.16%
377,306
+65
+0% +$674
PGNX
96
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$3.7M 0.15%
619,400
+555,401
+868% +$3.5M
INFI
97
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$3.7M 0.15%
2,649
+784
+42% +$12K
CERN
98
PUT
DELISTED
Cerner Corp
CERN
$3.66M 0.15%
+499
New +$34.5K
THMO
99
DELISTED
ThermoGenesis Holdings, Inc. Common Stock
THMO
$3.59M 0.15%
444
+33
+8% +$278K
OPK icon
100
PUT
Opko Health
OPK
$1.23B
$3.54M 0.15%
2,500
+1,223
+96% +$15.9K
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sabby Management held 367 positions worth $2.4B, up 75,773% from $3.17M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management deployed $169M of net new capital in Q1 2015, opening 126 new positions and adding to 77 existing holdings. Its largest new stake was Tempest Therapeutics: 709 shares worth $4.69M.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, up from 9.2% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $11.1M trimmed.

  • Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
  • Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
  • Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
  • Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
  • Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
  • Sabby Management opened 126 new positions and closed 85 in Q1 2015.
  • Sabby Management's portfolio value rose 75,773% quarter-over-quarter to $2.4B.

Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.